2022 Revenues ($USD) : $30,636,784,577.00
2022 Revenues (foreign currencies) : JP¥4,027,478,000,000
2022 R&D spend : $4,817,475,272.00
2022 Number of Employees : 47,347
Fiscal Year End : 03/31/22
Leader : CEO Christophe Weber

The Japanese pharma giant Takeda has a presence in approximately 80 countries and draws nearly half of its revenue from the U.S. The company continues to have a robust pipeline of around 40 clinical-stage assets. In March 2023, Takeda received approval to manufacture and market Entyvio subcutaneous injections in Japan for the maintenance treatment of moderate to severe ulcerative colitis. In February 2023, the FDA approved Takhzyro (lanadelumab-flyo) to prevent hereditary angioedema (HAE) attacks in children 2 years of age and older. Takeda also announced positive results in a Phase 2b study of investigational TAK-279, an oral, once-daily TYK2 inhibitor, in people with moderate-to-severe plaque psoriasis in March 2023. The company presently has 10 advanced-stage development programs, which offer upcoming opportunities for new molecular entity filings and expansion. —BB